polyclonal mpo primary antibody  (Elabscience Biotechnology)

Journal: Journal of Neuroinflammation

Article Title: Impact of the neutrophil response to granulocyte colony-stimulating factor on the risk of hemorrhage when used in combination with tissue plasminogen activator during the acute phase of experimental stroke

doi: 10.1186/1742-2094-11-96

Figure Lengend Snippet: Effect of subcutaneous administration of G-CSF (60 μg/kg; 30 μL) or vehicle (NaCl 0.9% , 30 μL). (a) on infarct volume (corrected for edema). Volumes are expressed in mm3 (mean ± SEM). * P <0.05; (b) on neutrophil infiltration in infarct area. Infiltration was quantified by counting positive cells to anti-myeloperoxidase antibody on six adjacent fields of 1 mm 2 on ischemic zone. All rats underwent ischemia/reperfusion, tPA treatment, and 72 hours of reperfusion. Values are mean ± SEM. * P <0.05. Scale bar: 100 μm. G-CSF, granulocyte colony stimulating factor; SEM standard error of the mean; PMN, polymorphonuclear neutrophils.

Article Snippet: Neutrophil infiltration was quantified after 72 hours of blood flow restoration by assaying myeloperoxidase (MPO), an enzyme expressed by neutrophil cells, using a rabbit polyclonal anti-MPO primary antibody (DAKO, Les Ulis, Franceand revealed by treatment with an avidin: biotinylated enzyme complex (PK-6100, ABC kit, Vector Labs, Burlingame, United States), as previously described [ ].

Techniques:

Journal: Frontiers in Physiology

Article Title: Effects of erythropoietin on osteoblast in the tooth extraction socket in mice periodontitis model

doi: 10.3389/fphys.2022.987625

Figure Lengend Snippet: Representative photomicrographs of alveolar tissue sections stained with vascular endothelial markers and the inflammatory marker in the control group (A,C,E,G,I,K) and EPO group (B,D,F,H,J,L) at 1 and 5 days. On day 1, the EPO group show stronger expression of cluster of differentiation 31 (CD31) and vascular endothelial growth factor (VEGF) in the entire extraction socket, especially in the apical and middle one-third of the regions compared to the control (A′,B′,E′,F′) . On day 5, the localization patterns are intensified in the EPO group compared to those observed on day 1 (B′,D′,F′,H′) . The EPO group also show a much stronger localization pattern, especially in the coronal 1/3 compared to that in the apical 1/3 and middle 1/3 regions (B′,D′,F′,H′) . In contrast, the EPO group showed decreased immunolocalization of myeloperoxidase (MPO) in both 1- and 5-day specimens (I′,J′,K′,L′) . Red arrows point to positive cells against CD31 (A–D) , VEGF (E–H) , and MPO (I–L) . Scale bar: X = 100 μm, X’ = 20 μm (X′ is higher magnification of X).

Article Snippet: Primary antibodies against inflammatory marker myeloperoxidase (MPO; cat. No. bs-4943R; 1:250; Bioss Antibodies, United States), osteocalcin (cat. ab93876; 1:250, Abcam, United Kingdom), and runt-related transcription factor 2 (RUNX2; cat. No. ab192256; 1:1000; Abcam, United Kingdom) were used to investigate bone formation and differentiation.

Techniques: Staining, Marker, Expressing